ArticleInternational journal of clinical oncology2020

Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation.

Yasutomo Teshima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.